13 May, 2017
$32.27M worth of stock was bought by Sanofi on Wednesday, January 11. The original version of this piece can be viewed at https://www.themarketsdaily.com/2017/05/11/hc-wainwright-reiterates-13-00-price-target-for-inovio-pharmaceuticals-inc-ino.html.
INO has been the subject of a number of other reports.
Stock market analysts and brokers have recently amended their target prices on shares of Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. (INO), a part of Healthcare sector and belongs to Biotechnology industry; ended its day with gain 1.43% and finalized at the price of $6.38. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a hold rating to a buy rating and set a $416.00 price objective for the company in a research note on Thursday, April 27th. They now have a United States dollars 421 price target on the stock.
02/10/2017 - Regeneron Pharmaceuticals, Inc. had its " rating reiterated by analysts at Sanford C. Bernstein. Buy rating has been given by 0 analysts to the company stock whereas no analyst given UNDERPERFORM rating to stock and 3 analysts given HOLD rating. In a transaction dated August 29, 2016, the shares were put up for sale at an average price of $9.3, raking in a sum of $202,740.
Inovio Pharmaceuticals (NASDAQ:INO) traded down 1.601% on Monday, hitting $6.455. Korea Investment CORP now owns 298 shares of the biopharmaceutical company's stock worth $115,000 after buying an additional 206 shares during the period. Regeneron Pharmaceuticals Inc has a 52 week low of $325.35 and a 52 week high of $452.96. Company's distance from 20 day simple moving average is 11.00% and distance from 50-Day simple moving average is 11.60%. The company has market cap of $57.82 million.
If we look at stock performance in last active day trading, we see that stock has moved remains unchanged to end the day at $4.02. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.31). Regeneron Pharmaceuticals had a net margin of 18.10% and a return on equity of 22.51%. The business had revenue of $1.32 billion for the quarter, compared to analysts' expectations of $1.30 billion. During the same quarter in the previous year, the company posted $0.07 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals will post $12.67 EPS for the current year.
11/07/2016 - Aegis Capital began new coverage on Inovio Pharmaceuticals, Inc. giving the company a "buy" rating. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & global trademark and copyright law. The firm owned 1,260 shares of the biopharmaceutical company's stock after buying an additional 133 shares during the period. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The biggest holder now is Kim Jong Joseph who owns 2,091,297 shares (2.81% of those outstanding), whilst Tee Khiang Ng holds 1,113,923 (1.50% of shares outstanding) and Mr. David B. Weiner holds 738,956 (0.99% of shares outstanding). Following the completion of the transaction, the chief executive officer now owns 2,164,887 shares of the company's stock, valued at $14,158,360.98. The disclosure for this sale can be found here.
Several other equities research analysts also recently commented on the stock. Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $291,560,000. Stoneridge Investment Partners LLC raised its stake in shares of Inovio Pharmaceuticals by 44.4% in the third quarter. Corporate insiders own 10.40% of the company's stock. Finally, Keybank National Association OH increased its position in Inovio Pharmaceuticals by 6.9% in the fourth quarter. New York State Common Retirement Fund now owns 230,458 shares of the biopharmaceutical company's stock worth $2,148,000 after buying an additional 56,631 shares during the last quarter. Inovio Pharmaceuticals had 9 analyst reports since August 10, 2015 according to SRatingsIntel. Emerald Advisers Inc. PA now owns 203,737 shares of the biopharmaceutical company's stock valued at $1,899,000 after buying an additional 48,751 shares in the last quarter. Cetera Advisors LLC increased its position in shares of Inovio Pharmaceuticals by 8.7% in the third quarter. Vident Investment Advisory LLC now owns 106,147 shares of the biopharmaceutical company's stock valued at $737,000 after buying an additional 42,764 shares during the last quarter.
